Alefacept(TD-HY113036) is a research-grade recombinant antibody targetingCD2. Produced in mammalian cells with native-like glycosylation.HighlightsResearch Grade— For PK/PD studies, assay development, and ADA research.Native Glycosylation— Mammalian expression ensures native-like patterns.
Species reactivity
Human
Applications
ELISA, Functional assay, Research in vivo
Isotype
Fusion - [CD58 (LFA3, lymphocyte function associated antigen 3)]2 - IGHG1 Fc (Fragment constant)
Protein A/G purified from cell culture supernatant.
Accession
P06729
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.
Alternate Names
CD58-Fc, LFA3-Fc, 222535-22-0
Background
Alefacept (BG 9273) is a human lymphocyte function-associated antigen 3/immunoglobulin 1 fusion protein. Alefacept can be used for the research of chronic plaque psoriasis.
Caption
Detects CD2 in indirect ELISAs. | SDS-PAGE for Research Grade Alefacept
Note
For research use only. Not suitable for clinical or therapeutic use.
抗体
试剂盒
多肽
蛋白
组织芯片
定制服务咨询